[This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovist™, now ABLAVARt™), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.

(EPI) Echo planar imaging is one of the early magnetic resonance imaging sequences (also known as Intascan), used in applications like diffusion, perfusion, and functional magnetic resonance imaging. Other sequences acquire one k-space line at each phase encoding step. When the echo planar imaging acquisition strategy is used, the complete image is formed from a single data sample (all k-space lines are measured in one repetition time) of a gradient echo or spin echo sequence (see single shot technique) with an acquisition time of about 20 to 100 ms. The pulse sequence timing diagram illustrates an echo planar imaging sequence from spin echo type with eight echo train pulses. (See also Pulse Sequence Timing Diagram, for a description of the components.)
In case of a gradient echo based EPI sequence the initial part is very similar to a standard gradient echo sequence. By periodically fast reversing the readout or frequency encoding gradient, a train of echoes is generated.
EPI requires higher performance from the MRI scanner like much larger gradient amplitudes. The scan time is dependent on the spatial resolution required, the strength of the applied gradient fields and the time the machine needs to ramp the gradients.
In EPI, there is water fat shift in the phase encoding direction due to phase accumulations. To minimize water fat shift (WFS) in the phase direction fat suppression and a wide bandwidth (BW) are selected. On a typical EPI sequence, there is virtually no time at all for the flat top of the gradient waveform. The problem is solved by "ramp sampling" through most of the rise and fall time to improve image resolution.
The benefits of the fast imaging time are not without cost. EPI is relatively demanding on the scanner hardware, in particular on gradient strengths, gradient switching times, and receiver bandwidth. In addition, EPI is extremely sensitive to image artifacts and distortions.

(EPI Factor) The imaging speed in Echo Planar Imaging (EPI) depends on many factors. Single shot EPI should provide images within 100 ms or less. Because of this limitations, a multi shot EPI approach is in most cases preferred. The parameter 'EPI Factor' is used to specify the number of k-space profiles collected per excitation.
The EPI factor 64 means a measurement time 64 times faster than a normal gradient echo sequence. See also Echo Planar Imaging.

A strategy for incrementing the position of the k-space trajectory of an echo planar imaging (EPI) pulse sequence.
Echo planar imaging (EPI) uses a constant gradient amplitude in one direction. This, combined with an oscillating gradient system in the frequency encoding direction, produces a zigzag trajectory in k-space. In the blipped phase encoding variant of EPI, the k-space position in the phase encoded direction is incremented by gradient 'blips' of the appropriate area. These, when timed to occur during the reversals of the read-out gradient, produce a rectilinear path in k-space.
The artifacts in an EPI image can arise from both hardware and sample imperfections. These are most easily understandable from examination of the k-space trajectory involved, which is either a zigzag form (when using a constant phase encoding gradient) or a rastered zigzag (when the phase encoding is performed with small gradients at the end of each scan line, so-called 'blipped' EPI).

From ISOL Technology

'Next generation MRI system 1.5T CHORUS developed by ISOL Technology is optimized for both clinical diagnostic imaging and for research development.
CHORUS offers the complete range of feature oriented advanced imaging techniques- for both clinical routine and research. The compact short bore magnet, the patient friendly design and the gradient technology make the innovation to new degree of perfection in magnetic resonance.'